HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Canfield, C. J. Articles by Jacobus, D. P. Search for Related Content PubMed PubMed Citation Articles by Canfield, C. J. Articles by Jacobus, D. P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATOVAQUONE SULFAMETHOXAZOLE

PS-15: a Potent, Orally Active Antimalarial from a New Class of Folic Acid Antagonists

A new, orally-active inhibitor of dihydrofolic acid reductase (DHFR), PS-15 (N-(3-(2,4,5-trichlorophenoxy)propyloxy)-N'-(1-methylethyl)-imidocarbonimidicdiamide hydrochloride), has significant activity against drug-resistant Plasmodium falciparum. It is not cross-resistant with other inhibitors of DHFR (e.g., pyrimethamine and cycloguanil). Although it bears similarities to proguanil, PS-15 represents a new antifolate class of drugs that we have named oxyguanils or hydroxylamine-derived biguanides. This compound displays intrinsic antimalarial activity and also is metabolized in vivo to WR99210, an extremely active triazine inhibitor of DHFR. When tested in vitro against drug-resistant clones of P. falciparum, PS-15 was more active than proguanil, and the putative metabolite, WR99210, was more active than the proguanil metabolite cycloguanil. The drug is also more active as well as less toxic than proguanil when administered orally to mice infected with P. berghei. When administered orally to Aotus monkeys infected with multidrug-resistant P. falciparum, PS-15 was more active than either proguanil or WR99210. In 1973, WR99210 underwent clinical trials for safety and tolerance in volunteers. The trials showed gastrointestinal intolerance and limited bioavailability; further development of the drug was abandoned. Because PS-15 has intrinsic antimalarial activity, is not cross-resistant with other DHFR inhibitors, and can be metabolized to WR99210 in vivo, oral administration of this new drug should circumvent the shortcomings and retain the advantages found with both proguanil and WR99210.

This article has been cited by other articles:

				D. S. Diaz, Michael. P. Kozar, K. S. Smith, C. O. Asher, J. C. Sousa, G. A. Schiehser, David. P. Jacobus, Wilbur. K. Milhous, Donald. R. Skillman, and Todd. W. Shearer Role of Specific Cytochrome P450 Isoforms in the Conversion of Phenoxypropoxybiguanide Analogs in Human Liver Microsomes to Potent Antimalarial Dihydrotriazines Drug Metab. Dispos., February 1, 2008; 36(2): 380 - 385. [Abstract] [Full Text] [PDF]

				M. D. Edstein, B. M. Kotecka, A. L. Ager, K. S. Smith, C. A. DiTusa, D. S. Diaz, D. E. Kyle, G. A. Schiehser, D. P. Jacobus, K. H. Rieckmann, et al. Antimalarial pharmacodynamics and pharmacokinetics of a third-generation antifolate JPC2056 in cynomolgus monkeys using an in vivo in vitro model J. Antimicrob. Chemother., October 1, 2007; 60(4): 811 - 818. [Abstract] [Full Text] [PDF]

				A. Nzila The past, present and future of antifolates in the treatment of Plasmodium falciparum infection J. Antimicrob. Chemother., June 1, 2006; 57(6): 1043 - 1054. [Abstract] [Full Text] [PDF]

				M. D. Hastings and C. H. Sibley Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax PNAS, October 1, 2002; 99(20): 13137 - 13141. [Abstract] [Full Text] [PDF]